Aperio Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Aperio Group’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-43,434	Closed	-$781K	–	2414
2020 Q2	$781K	Buy	43,434 +3,779	+10%	+$52.6K	﹤0.01%	1537
2020 Q1	$283K	Buy	+39,655	New	+$495K	﹤0.01%	1939
2019 Q4	–	Sell	-8,463	Closed	-$227K	–	2359
2019 Q3	$227K	Buy	8,463 +2,863	+51%	+$80.4K	﹤0.01%	2130
2019 Q2	$152K	Buy	+5,600	New	+$176K	﹤0.01%	2273
2018 Q1	–	Sell	-4,770	Closed	-$232K	–	2280
2017 Q4	$232K	Buy	4,770 +356	+8%	+$18K	﹤0.01%	2082
2017 Q3	$238K	Sell	4,414 -44	-1%	-$2.58K	﹤0.01%	2046
2017 Q2	$250K	Buy	+4,458	New	+$179K	﹤0.01%	1992

Aperio Group's PTLA Position: Q3 2020 in Review

Aperio Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 43,434 shares — an estimated $781K sold.

Aperio Group first reported a position in PTLA in Q2 2017 and held it in 7 quarters. The position peaked at $781K in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

Aperio Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Aperio Group sold 43,434 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $781K.
Aperio Group first reported a position in Portola Pharmaceuticals, Inc. in Q2 2017 and held it in 7 quarters.
Aperio Group's Portola Pharmaceuticals, Inc. position peaked at $781K in Q2 2020.
0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Aperio Group's 13F filing for Q3 2020, filed 6 Nov 2020.